awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q36933601-03087843-4B46-44DD-8B19-8967773DB07C
Q36933601-03087843-4B46-44DD-8B19-8967773DB07C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36933601-03087843-4B46-44DD-8B19-8967773DB07C
Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study
P2860
Q36933601-03087843-4B46-44DD-8B19-8967773DB07C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36933601-03087843-4B46-44DD-8B19-8967773DB07C
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
caaecf4b7a66125eb2dae68e12c230120fb46fd9
P2860
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati